Daparol 5 mg (Tablet)
Unit Price: ৳ 16.00 (1 x 14: ৳ 224.00)
Strip Price: ৳ 224.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Dapagliflozin propanediol |
| Company | Drug international ltd |
Indications
- Adjunct to diet and exercise
- Improves glycemic control
- Type 2 diabetes mellitus
Pharmacology
- Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
- Reduces reabsorption of filtered glucose
- Lowers the renal threshold for glucose
- Increases urinary glucose excretion
Dosage & Administration
- Recommended starting dose of 5 mg once daily
- Can be taken with or without food
- Dose can be increased to 10 mg once daily
- Assessment of renal function is recommended prior to initiation of therapy
- No dose adjustment needed in patients with mild renal impairment
Interaction
- May add to the diuretic effect of thiazide and loop diuretics
- Increases the risk of dehydration and hypotension
- Can interact with insulin and insulin secretagogues
- Interacts with antihypertensives, pioglitazone, ACE inhibitors, angiotensin II antagonists, GLP-1 agonists, valsartan, rifampin, mefenamic acid
Contraindications
- Known hypersensitivity to Dapagliflozin or excipients
- Severe renal impairment
- End-stage renal diseases
- Patients on dialysis
Side Effects
- Hypotension
- Ketoacidosis
- Acute kidney injury
- Impairment in renal function
- Urosepsis and pyelonephritis
- Hypoglycemia with concomitant use with insulin and insulin secretagogues
- Genital mycotic infections
- Increases in low-density lipoprotein cholesterol (LDL-C)
- Nasopharyngitis
- Urinary tract infection
- Bladder cancer
Pregnancy & Lactation
- Pregnancy category C
- Use during pregnancy only if potential benefit justifies potential risk to the fetus
- Should not be used during lactation
Precautions & Warnings
- Assess volume status and correct hypovolemia before initiating Daparol
- Monitor for signs and symptoms of hypotension during therapy
- Monitor renal function during therapy
- Consider lower dose of insulin or insulin secretagogue
- Use with caution in patients with a prior history of bladder cancer
Therapeutic Class
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
- Store in a cool place below 30°C
- Keep away from light
- Keep away from the reach of children